ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Post by MYSTICALon Jun 22, 2016 8:32am

145 Views

Post# 24986461

TSX Volume Actives 2nd most active

TSX Percent Gainers

16 h 17 HE, 21 juin 2016

Nom	Symbole	Dern. cours	Var.	Var. %	Ouverture	Haut	Bas	Volume
Marret Multi-Strategy Income Fund	T.MMF.UN	0,04	0,02	100,00 %	s.o.	s.o.	s.o.	1 000,00
ProMIS Neurosciences Inc.	T.PMN	0,195	0,085	77,27 %	s.o.	s.o.	s.o.	2,66m
Lanesborough Real Estate Investment Trust	T.LRT.UN	0,11	0,025	29,41 %	s.o.	s.o.	s.o.	5,00k